June 06, 2026
4 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Once-daily GLP-1/GIP dual agonist lowers HbA1c, weight in type 1 diabetes
NEW ORLEANS — A once-daily GLP-1/GIP dual agonist reduced HbA1c and body weight at 16 weeks among adults with type 1 diabetes, according to findings from a phase 2 trial presented at the American Diabetes Association Scientific Sessions.Acmopatide (Roche), formerly known as CT-868, delivered a wide range of benefits among people with type 1 diabetes. Beyond improvements in HbA1c and body
1,199 words~5 min read
